JP2012507268A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012507268A5 JP2012507268A5 JP2011533565A JP2011533565A JP2012507268A5 JP 2012507268 A5 JP2012507268 A5 JP 2012507268A5 JP 2011533565 A JP2011533565 A JP 2011533565A JP 2011533565 A JP2011533565 A JP 2011533565A JP 2012507268 A5 JP2012507268 A5 JP 2012507268A5
- Authority
- JP
- Japan
- Prior art keywords
- meteef1a
- metap2
- concentration
- activity
- compound
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08019432.7 | 2008-11-06 | ||
| EP08019432 | 2008-11-06 | ||
| PCT/EP2009/007102 WO2010051882A1 (en) | 2008-11-06 | 2009-10-05 | Use of eef1a as biomarker and a method of screening metap2 inhibitors |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2012507268A JP2012507268A (ja) | 2012-03-29 |
| JP2012507268A5 true JP2012507268A5 (enExample) | 2012-11-22 |
| JP5347028B2 JP5347028B2 (ja) | 2013-11-20 |
Family
ID=41409225
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2011533565A Active JP5347028B2 (ja) | 2008-11-06 | 2009-10-05 | バイオマーカーとしてのＥＥＦ１Ａの使用およびＭｅｔＡＰ２阻害剤をスクリーニングするための方法 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US9151743B2 (enExample) |
| EP (1) | EP2344665B1 (enExample) |
| JP (1) | JP5347028B2 (enExample) |
| AU (1) | AU2009313167C1 (enExample) |
| CA (1) | CA2742737C (enExample) |
| ES (1) | ES2402564T3 (enExample) |
| IL (1) | IL212664A0 (enExample) |
| WO (1) | WO2010051882A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015069489A1 (en) | 2013-11-06 | 2015-05-14 | Merck Patent Gmbh | Predictive biomarker for hypoxia-activated prodrug therapy |
| KR101712982B1 (ko) * | 2015-07-31 | 2017-03-07 | 고려대학교 산학협력단 | 비알콜성지방간 조절인자 14-3-3 단백질 |
| US20200030278A1 (en) * | 2017-02-10 | 2020-01-30 | Zafgen, Inc. | Pharmaceutical compositions of metap-2 inhibitors |
| CN108611352B (zh) * | 2018-04-20 | 2020-08-07 | 华南农业大学 | 一种拟禾本科根结线虫翻译延长因子Mg-eEF1A及其防治植物病害的应用 |
| CN115461054A (zh) * | 2020-02-06 | 2022-12-09 | 加利福尼亚大学董事会 | 延伸因子1-α抑制剂及其用途 |
| CN116395718B (zh) * | 2023-04-12 | 2024-12-17 | 中国科学院长春应用化学研究所 | 一种弱碱性钠盐纳米药物、其制备方法及其应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1998056372A1 (en) * | 1997-06-09 | 1998-12-17 | Massachusetts Institute Of Technology | TYPE 2 METHIONINE AMINOPEPTIDASE (MetAP2) INHIBITORS AND USES THEROF |
| WO2002039990A2 (en) * | 2000-11-14 | 2002-05-23 | Novartis Ag | Method for screening anti-proliferative compounds and inhibiting tumor growth |
| US20020182701A1 (en) * | 2001-08-30 | 2002-12-05 | Saint Louis University | Dominant negative variants of methionine aminopeptidase 2 (MetAP2) and clinical uses thereof |
| US20030232383A1 (en) | 2001-11-02 | 2003-12-18 | Sylvia Daunert | Novel reagentless sensing system for measuring carbohydrates based on the galactose/glucose binding protein |
-
2009
- 2009-10-05 ES ES09778819T patent/ES2402564T3/es active Active
- 2009-10-05 CA CA2742737A patent/CA2742737C/en active Active
- 2009-10-05 AU AU2009313167A patent/AU2009313167C1/en active Active
- 2009-10-05 WO PCT/EP2009/007102 patent/WO2010051882A1/en not_active Ceased
- 2009-10-05 US US13/127,834 patent/US9151743B2/en active Active
- 2009-10-05 EP EP09778819A patent/EP2344665B1/en active Active
- 2009-10-05 JP JP2011533565A patent/JP5347028B2/ja active Active
-
2011
- 2011-05-03 IL IL212664A patent/IL212664A0/en active IP Right Grant
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10329354B2 (en) | Modulation of efferocytosis pathways for treatment of atherosclerotic disease | |
| Shere et al. | Circulating blood biomarkers in essential hypertension: a literature review | |
| CN104569436B (zh) | Adamts1作为主动脉夹层临床筛查分子标记物的应用 | |
| KR102266302B1 (ko) | 심혈관 질환 또는 문제 위험 예측용 방법 및 키트 | |
| JP2012507268A5 (enExample) | ||
| Salah et al. | MCP-1 promotes detrimental cardiac physiology, pulmonary edema, and death in the cpk model of polycystic kidney disease | |
| Cirillo et al. | Increased high mobility group box-1 protein levels are associated with impaired cardiopulmonary and echocardiographic findings after acute myocardial infarction | |
| RU2609649C2 (ru) | Блокада сигнализации ccl18 через ccr6 как терапевтический способ лечения при фиброзных заболеваниях и раке | |
| CN114752669A (zh) | 一种环状rna在制备脑卒中诊断产品中的应用 | |
| ES2665849T3 (es) | Biomarcador para el diagnóstico de envejecimiento o amiotrofia | |
| Ablooglu et al. | Intrinsic endothelial hyperresponsiveness to inflammatory mediators drives acute episodes in models of Clarkson disease | |
| Tanios et al. | CXCR4: a potential marker for inflammatory activity in abdominal aortic aneurysm wall | |
| JP2019200077A (ja) | 肝細胞癌の診断マーカー | |
| JP2011519030A (ja) | ヒトおよび動物における生物学的老化、再生能、発癌リスク、加齢性疾患を発症するリスクおよび慢性疾患の予後を測定するための、ｄｎａ損傷およびテロメア機能不全を測定するためのマーカー | |
| TWI359271B (en) | Pharmaceutical composition for insulin resistance | |
| Xu et al. | Serum CIAPIN1 is lower in septic patients with cardiac dysfunction | |
| US20230192882A1 (en) | Use Of Biomarker Or Biomarkers Combinations In Preparing A Diagnostic Reagent For Fulminant Myocarditis And A Drug For Fulminant Myocarditis | |
| Slevin et al. | Intestinal expression of LAG-3 correlates with inflammatory activity and response to biological therapy in ulcerative colitis | |
| van der Velde et al. | Cardiovascular biomarkers: translational aspects of hypertension, atherosclerosis, and heart failure in drug development | |
| Wang et al. | PIN1, a perspective on genetic biomarker for nonalcoholic fatty liver disease (NAFLD) | |
| Chen et al. | Interleukin-6-634C> G polymorphism in hypertensive patients with and without left ventricular hypertrophy | |
| JP7525591B2 (ja) | 心機能不全を予測及び処置するための方法 | |
| JP2012127879A (ja) | 腎症の進行度の判定方法並びに線維化抑制剤。 | |
| Yamada et al. | CTRP7 as a molecular biomarker for predicting responsiveness to pulmonary vasodilators: insights from human and animal studies in pulmonary arterial hypertension | |
| Smith | Extracellular Matrix Remodelling in Age-Related Sinus Node Disease |